subject: Hepatitis B - Drug Pipeline Analysis And Market Forecasts To 2016---aarkstore Enterprise Market [print this page] Hepatitis B - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global hepatitis B market. The report identifies the key trends shaping and driving the global hepatitis B market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hepatitis B (Hep B)sector.
Analysis revealed that the market grew at a Compound Annual Growth Rate (CAGR) of 5.9% since 2001 to reach $879m in 2009. Growth in the Hep B market will be driven by the increasing number of patients over the next few years. The current Hep B market is dominated by anti-viral therapies and this trend likely to continue, with no innovative molecules in the developmental pipeline. Analysis showed that the Hep B pipeline is weak in terms of the number of molecules. The pipeline molecules in the Hep B market primarily comprise of me-too molecules (five), and combination therapies (five), with efficacy and safety profiles similar to the present therapeutic options. The most promising molecules among them are combinations of entecavir plus adefovir and tenofovir plus emtricitabine.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.
Scope
The scope of the report includes:
- Annualized global Hep B market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action are nucleoside/nucleotide anti-virals, glucocorticoids and Natural Killer Ts (NKTs).
- Analysis of the current and future market competition in the global Hep B market. The key market players covered are Bristol-Myers Squibb and Gilead Science Inc.
- Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, unmet needs, and the implications for the future market associated with Hep B.
